Seeking Alpha

AVI BioPharma (AVII +1.5%) says an independent data safety monitoring board has found no safety...

AVI BioPharma (AVII +1.5%) says an independent data safety monitoring board has found no safety concerns for its Phase IIb study of eteplirsen in Duchenne Muscular Dystrophy patients. The board has now given the go signal for the company to proceed with the trial as planned.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs